Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rallybio Corp RLYB

Healthcare Biotechnology
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.


NDAQ:RLYB - Post by User

Rallybio Corp
Bullboard Posts
Next >>
User Avatar Image
(267)
•••
Post by whytestockson Apr 11, 2024 10:00am
40 Views
Post# 35983113

Rare Disease-Focused Rallybio Inks Development Pact With Joh

Rare Disease-Focused Rallybio Inks Development Pact With Joh
Breaking News: $RLYB Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher | BenzingaRallybio Corporation (NASDAQ:RLYB) shares are trading higher after the company announced a collaboration with Johnson & Johnson ...RLYB - Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher | Benzinga

Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities